Download PDF

Placebo and Nocebo Effects¶

Chapter 496 | Part 20: Emerging Topics in Clinical Medicine · Parts 19-20 – Consultative & Emerging Topics · Chapter 496

Key Clinical Points¶

Placebo effect is a positive change in clinical outcome attributed to psychological, neurological, or physiological mechanisms.
Nocebo effect involves negative changes/side effects resulting from negative information or cues.
Approximately 25% of patients in placebo arms of clinical trials report side effects.
The 'placebome' includes genes like COMT, MAO-A, OPRM1, TPH2, and HTR2A that influence response.
Open-hidden designs show that not disclosing a drug's identity can result in a 30% loss of efficacy even for potent opioids.
Clinician 'warmth' and 'competence' are critical factors in modulating patient expectations and outcomes.
White coat hypertension is a common example of an environmental/contextual response to medical settings.
Open-label placebos (OLPs) have shown significant overall effects in conditions like IBS and chronic back pain.
Pharmacogenomics can reveal that different genotypes (e.g., A/A vs. a/a) may show distinct drug vs. placebo responses.
Placebo response is not just a 'nuisance' but an integral component of the total treatment effect.

DEFINITION & CLASSIFICATION¶

• Placebo: Sham versions of drugs, devices, or surgeries that lack the active compound, function, or procedure they are designed to simulate. • Placebo response: Improvement observed among patients assigned to placebo treatment in a clinical trial. • Placebo effect: Positive change in clinical outcome observed after a placebo treatment; an exclusively attributed expectation mediated by psychological, neurological, or physiological placebo mechanisms. • Nocebo effect: Side effect or negative change in clinical outcome observed after exposure to negative information, interactions, or cues that can induce negative expectations. • Open-label placebos (OLPs): Placebos administered to patients with their full knowledge that the treatment lacks the active pharmaceutical agent.

Glossary of Terms¶

• Additivity in clinical trials: > Definition (Harrison's 22e): The assumption that placebo and drug treatment responses are additive is a fundamental assumption in clinical trials. However, there are notable exceptions to this assumption in pharmacogenomic and brain imaging studies where subsets of the population have been reported to have differential effects in placebo and drug treatment arms of a trial. • Expectation: > Definition (Harrison's 22e): A specific belief about the future based on a prediction of what is most likely to happen. Examples: 'This drug will relieve my pain'; 'I will experience side effects.' • Implicit learning: > Definition (Harrison's 22e): The nonconscious acquisition of knowledge. Classical conditioning, a form of implicit learning, is implicated in certain instances of the placebo effect (e.g., implicit association of sleepiness with the administration of blue pills). • Neurobiological mechanisms: > Definition (Harrison's 22e): Dopamine, endogenous opioids, and endocannabinoids are three of the major neurotransmitter systems implicated in moderating the placebo effect. Placebo effects also work by activating biological properties of the body that facilitate healing, including homeostatic mechanisms and immune and inflammatory responses. These contribute to the natural history of a disease but can also be targets of placebo effects. • Placebome: > Definition (Harrison's 22e): The genome-related products that modify placebo response. Several genes in neurotransmitter and other pathways have been implicated in modifying response to placebo treatment in clinical trials. The most well-studied of these is in the gene encoding catechol-O-methyltransferase (COMT). • Social and observational learning: > Definition (Harrison's 22e): Learning through direct observation of others undergoing treatment (i.e., other patients) and interactions with individuals who wield influence over the patient (i.e., physicians and nurses) both may powerfully drive placebo effects. • Treatment: > Definition (Harrison's 22e): The specific characteristics include factors like the shape, color, and labeling of the treatment; the method of administration; and the characteristics physical environment in which the treatment is administered.

EPIDEMIOLOGY¶

• Clinical Scope: Documented in pain, depression, Parkinson's disease, anxiety disorders, cardiovascular disorders, cancer-related fatigue, asthma, and gastrointestinal disorders. • Outcome Types: Affects both patient-reported outcomes and objective physiologic outcomes (e.g., blood pressure, immune biomarkers, exercise endurance, cognitive scores). • Trial Statistics: → Average of 25% of participants in placebo arms report side effects. → Some drugs (e.g., statins) show no significant difference in side effect rates between active drug and placebo. • Management of Placebo Response in Trials: 1. Timing: In Alzheimer's, trials are designed to last beyond the 8-week period where placebo response is maximal. 2. Placebo run-in design: All patients start on placebo → those responding to placebo are excluded. 3. Sequential parallel comparison design (SPCD): Patients randomized 2:1 to placebo or drug → after brief period, non-responders to placebo are re-randomized. • Current Status: No method currently exists that reliably eliminates the impact of placebo response on clinical trial failure.

ETIOLOGY & PATHOPHYSIOLOGY¶

• Core Concept: Total response = (Drug) + (Social/Psychological context imes Patient biology). • Integration: Placebo effects are not "nuisances" to subtract but integral components of the overall treatment effect.

Psychological Mechanisms¶

• Expectations: Primary driver of placebo effects. ◦ Can be conscious (e.g., belief that NSAIDs relieve pain). ◦ Can be conditioned (e.g., blue pills associated with sleepiness). • Mindsets: Core beliefs about a domain (e.g., "cancer is a catastrophe" or "my body is damaged"). ◦ Mindsets orient individuals to specific associations and goals. ◦ Difference: Expectation is a specific belief; Mindset is a broader, often more powerful, overarching belief.

• Language & Information: → Open-hidden design study: Patients told they received morphine → significantly greater effect than those who were not told. → Result: Opioids lose up to 30% efficacy if the patient is unaware of treatment. • Clinician Characteristics: → Two key factors: Perception of Competence (does the doctor "get it?") and Warmth (does the doctor "get me?"). → Interaction: High warmth + high competence → enhanced placebo effect; Low warmth/competence → minimized placebo/nocebo effects. • Symbols, Rituals, & Environment: → White coat hypertension: Transient BP rise in medical settings. → Physical attributes: Shape, color, and brand name impact efficacy. → Packaging: Capsules perceived as stronger than tablets; generic versions often have reduced response. → Labeling: "Maxalt" label > "Maxalt or placebo" label > "placebo" label. → Branding: Letters X and Z are less negatively associated; Z is linked to efficacy, T/S to tolerability.

Biological Mechanisms¶

• Neurochemistry: Evidence from the 1970s (naloxone) showed psychological factors affect physiology. ◦ Key systems: Dopamine, endogenous opioids, and endocannabinoids. ◦ Neuroimaging: Placebo analgesia correlates with reduced signaling in spinothalamic tract and increased signaling in frontal-parietal regions. • Meaning-making: Placebo treatments influence brain systems that construct internal models to interpret sensory signals. • The Placebome (Genetics): → Identified via GWAS of placebo arms. → Key genes: ◦ COMT & MAO-A (Dopamine metabolism). ◦ OPRM1 (Opioid receptor). ◦ TPH2 & HTR2A (Serotonin signaling). → Note: COMT has the strongest evidence for association with placebo response in IBS and pain.

CLINICAL FEATURES¶

• Nocebo Symptoms: Negative changes or side effects resulting from negative information/cues. • Placebo Response Signs: Positive clinical outcomes observed in the absence of active pharmacological agents.

DIFFERENTIAL DIAGNOSIS¶

• Placebo vs. Drug Effect: Distinguishing between a true pharmacological response and a response driven by psychological/social factors. • Natural History & Other Effects: Differentiating placebo from: → Regression to the mean. → Spontaneous remission. → Hawthorne effect (behavioral changes due to being observed).

DIAGNOSTIC APPROACH¶

Clinical Trial Design: Use of double-blinding, randomization, and placebo controls to isolate the drug's specific efficacy.
Pharmacogenomic Analysis: Identifying specific alleles (e.g., A/A vs. a/a) where the drug effect is distinct from the placebo response.

MANAGEMENT & TREATMENT¶

Open-Label Placebos (OLPs): • Used in: IBS, chronic back pain, allergic rhinitis, cancer-related fatigue, ADHD, major depression, and menopausal hot flushes. • Evidence: Meta-analysis shows significant overall effect.
Ethical Considerations: • Requirement: Informed consent is mandatory for all trials. • Controversy: Use of "impure" placebos (active drugs at sub-therapeutic doses) remains a point of debate.

KEY PEARLS & HIGH-YIELD POINTS¶

• The 30% Rule: Opioids can lose up to 30% efficacy if the patient is not informed they are receiving the medication. • Clinician Impact: A physician's perceived warmth and competence are critical for maximizing placebo benefits and minimizing nocebo harms. • Placebome: The study of the placebome (e.g., COMT, MAO-A) allows for identifying subpopulations that may respond differently to treatment. • Trial Design: Placebo run-in and SPCD are specific methods used to mitigate the impact of placebo responders in clinical trials.

Reference Tables¶

TABLE 496-1 Glossary of Terms commonly used in Placebo Studies TERM Additivity in clinical trials The assumption that…¶

Harrison's 22e, p.3930

TERM	DEFINITION
Additivity in clinical trials	The assumption that placebo and drug treatment responses are additive is a fundamental assumption in clinical trials. However, there are notable exceptions to this assumption in pharmacogenomic and brain imaging studies where subsets of the population have been reported to have differential effects in placebo and drug treatment arms of a trial.
Expectation	A specific belief about the future based on a prediction of what is most likely to happen. Examples: “This drug will relieve my pain”; “I will experience side effects.”
Implicit learning	The nonconscious acquisition of knowledge. Classical conditioning, a form of implicit learning, is implicated in certain instances of the placebo effect (e.g., implicit association of sleepiness with the administration of blue pills).
Neurobiological mechanisms	Dopamine, endogenous opioids, and endocannabinoids are three of the major neurotransmitter systems implicated in moderating the placebo effect. Placebo effects also work by activating biological properties of the body that facilitate healing, including homeostatic mechanisms and immune and inflammatory responses. These contribute to the natural history of a disease but can also be targets of placebo effects.
Open-label placebos (OLPs)	OLPs are placebos administered to patients with their full knowledge that the treatment lacks the active pharmaceutical agent. OLP clinical trials have been conducted in irritable bowel syndrome, chronic back pain, allergic rhinitis, cancer-related fatigue, attention deficit hyperactivity disorder, major depression, and menopausal hot flushes. Meta-analysis of OLP trials found a significant overall effect.
Placebo	Placebos are sham versions of drugs, devices, or surgeries that lack the active compound, function, or procedure they are designed to simulate. Placebos are often used in clinical trials as controls for placebo effects, natural history, regression to the mean, spontaneous remission, and Hawthorne effects (the tendency for people to change their behaviors when being observed).
Placebo response	Improvement observed among patients assigned to placebo treatment in a clinical trial.
Social and observational learning	Learning through direct observation of others undergoing treatment (i.e., other patients) and interactions with individuals who weild influence over the patient (i.e., physicians and nurses) both may powerfully drive placebo effects.